Quel est le prix pour Orchard Therapeutics plc (ORTX)

Le prix pour Orchard Therapeutics plc (ORTX) est $16.70

Quelle est la capitalisation boursière pour Orchard Therapeutics plc (ORTX)

La capitalisation boursière pour Orchard Therapeutics plc (ORTX) est $210.34M

Orchard Therapeutics plc (ORTX) BPA

Orchard Therapeutics plc is a biopharmaceutical firm dedicated to developing gene-based treatments for severe and often fatal rare conditions, operating across the United Kingdom, European Union, and the United States. Their innovative gene therapy strategy involves modifying a patient's own hematopoietic stem cells, converting them into a therapeutic cellular drug that can address the illness with just one dose. The company markets Strimvelis, a gammaretroviral therapy approved for treating adenosine deaminase-severe combined immunodeficiency (ADA-SCID). Orchard's clinical pipeline features several investigational therapies, including OTL-101 for ADA-SCID, OTL-200 targeting metachromatic leukodystrophy, OTL-103 for Wiskott-Aldrich syndrome, OTL-102 for X-linked chronic granulomatous disease, and OTL-300 for transfusion-dependent beta-thalassemia. Early-stage research programs encompass OTL-203 for mucopolysaccharidosis type I, OTL-201 for MPS-IIIA, and OTL-202 for MPS IIIB. Furthermore, a strategic partnership with Pharming Group N.V. covers the research, development, production, and commercialization of OTL-105, an experimental ex vivo autologous hematopoietic stem cell gene therapy designed for hereditary angioedema. Established in 2015 as Orchard Rx Limited, Orchard Therapeutics plc is headquartered in London, UK.

Année	EPS	Changez
Pas assez de données pour les dates fournies.

Année

EPS

Changez

Pas assez de données pour les dates fournies.

Entreprise	EPS	Différence d’EPS	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Moderna, Inc. MRNA.US	$-7.98	-	US
CSL Limited CSL.AX	$-5.29	-	AU
Lonza Group AG LONN.SW	-	-	CH

Entreprise

EPS

Différence d’EPS

Pays